Superworth

Cogent Biosciences free cash flow COGT

Cash from operations less capital spending, by quarter and over the last twelve months, from 2017.

Last 12 months, to Jun 30, 2026
−$309.2M
Latest quarter, Q2 FY26
−$77.6M
Fiscal year 2025
−$266M

Cogent Biosciences' free cash flow was −$309.2M over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$77.6M.

Free cash flow over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearFree cash flowChange
FY2025−$266Mn/a
FY2024−$208.4Mn/a
FY2023−$156.4Mn/a
FY2022−$125.5Mn/a
FY2021n/an/a
FY2019−$41.5Mn/a
FY2018−$33Mn/a
FY2017−$26.7Mn/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedFree cash flowOn a year earlierLast 12 months
Q2 FY26−$77.6Mn/a−$309.2M
Q1 FY26−$87.3Mn/a−$286.3M
Q4 FY25−$79.9Mn/a−$266M
Q3 FY25−$64.4Mn/a−$246.7M
Q2 FY25−$54.7Mn/a−$234.6M
Q1 FY25−$67.1Mn/a−$222.8M
Q4 FY24−$60.7Mn/a−$208.4M
Q3 FY24−$52.3Mn/a−$192.1M
Q2 FY24−$42.8Mn/a−$177.9M
Q1 FY24−$52.6Mn/a−$168.4M
Q4 FY23−$44.4Mn/a−$156.4M
Q3 FY23−$38.1Mn/a−$143.4M

Against its peers

Companies in Drug Manufacturers - General nearest Cogent Biosciences' size, closest first, today.

CompanyFree cash flow yield
COGTCogent Biosciences−5.7%
KNSAKiniksa Pharmaceuticals International3.1%
LGNDLigand Pharmaceuticals2.2%
AMRXAmneal Pharmaceuticals2.0%
INDVIndivior Pharmaceuticals−2.7%
ALKSAlkermes plc.3.0%
ARQTArcutis Biotherapeutics1.0%
LQDALiquidia3.9%
OGNOrganon15.7%
TGTXTG Therapeutics0.2%
PTGXProtagonist Therapeutics1.5%
Peer median2.1%

What the free cash flow tells you

Cash from operations minus capital spending. The cash the company could hand back or reinvest.

Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.

More on Cogent Biosciences

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.